Yair Lotan, Peter C. Black, Laura Caba, Sam S. Chang, Michael S

Slides:

Advertisements

Similar presentations

Volume 62, Issue 4, Pages (October 2012)

Advertisements

Volume 68, Issue 2, Pages (August 2015)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

P. Therasse, S. Carbonnelle, J. Bogaerts

Volume 187, Issue 4, Pages e515-e516 (April 2012)

Testosterone Therapy in Men With Prostate Cancer

Global Trends in Testicular Cancer Incidence and Mortality

Volume 64, Issue 1, Pages (July 2013)

Volume 53, Issue 4, Pages (April 2008)

Volume 74, Issue 2, Pages (August 2018)

Volume 71, Issue 4, Pages (April 2017)

Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes Solomon L. Woldu, Joseph A. Moore,

Ashish M. Kamat, Sima Porten European Urology

Volume 73, Issue 5, Pages (May 2018)

European Urology Oncology

European Urology Oncology

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 68, Issue 3, Pages (September 2015)

P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes European Urology

Volume 69, Issue 3, Pages (March 2016)

Volume 60, Issue 4, Pages (October 2011)

Volume 64, Issue 3, Pages (September 2013)

Laurent Boccon-Gibod European Urology Supplements

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Stephen B. Williams, Ashish M

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 4, Pages (April 2008)

Volume 66, Issue 2, Pages (August 2014)

Rectal Injury During Radical Prostatectomy: Focus on Robotic Surgery

Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter,

Use of the National Health and Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on Cost and Prevalence of Urolithiasis in.

Volume 64, Issue 1, Pages (July 2013)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Volume 50, Issue 5, Pages (November 2006)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

European Urology Oncology

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

European Urology Oncology

Role of Checkpoint Inhibition in Localized Bladder Cancer

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Volume 74, Issue 4, Pages (October 2018)

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Functional and Oncologic Outcomes Between Open and Robotic Radical Prostatectomy at 24-month Follow-up in the Swedish LAPPRO Trial Martin Nyberg, Jonas.

Challenges and Opportunities in Hormone-Resistant Prostate Cancer

Jonathan S. Brajtbord, Michael S. Leapman, Matthew R. Cooperberg

Psychotherapeutic Interventions Targeting Prostate Cancer Patients: A Systematic Review of the Literature Liliana Vartolomei, Shahrokh F. Shariat, Mihai.

European Urology Oncology

Volume 74, Issue 6, Pages (December 2018)

The Cost to Medicare of Bladder Cancer Care

European Urology Oncology

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

European Urology Oncology

Volume 52, Issue 6, Pages (December 2007)

Volume 68, Issue 2, Pages (August 2015)

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Systematic Review of Complications of Prostate Biopsy

Volume 74, Issue 6, Pages (December 2018)

Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy Badrinath Konety, Neal Shore, Andrew Karim Kader, Sima Porten,

European Lung Cancer Conference (ELCC) 2016 Organisation

Salvage Local Treatments After Focal Therapy for Prostate Cancer

European Urology Oncology

Maximilian Burger, Ashish M. Kamat, David McConkey

How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder? Shahrokh Shariat, Paolo Gontero, James.

Robert Comis, MD, The Passing of a “Lung Man”

Morgan Rouprêt, Per-Uno Malmstrom, Peter Black

Presentation transcript:

Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review Yair Lotan, Peter C. Black, Laura Caba, Sam S. Chang, Michael S. Cookson, Siamak Daneshmand, Ashish M. Kamat, James M. McKiernan, Raj S. Pruthi, Chad R. Ritch, Gary D. Steinberg, Robert S. Svatek, Ellen C. Zwarthoff European Urology Oncology Volume 1, Issue 3, Pages 223-230 (August 2018) DOI: 10.1016/j.euo.2018.04.010 Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 1 Biomarker studies: experimental and nonexperimental study types with examples. PSA=prostate-specific antigen. European Urology Oncology 2018 1, 223-230DOI: (10.1016/j.euo.2018.04.010) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 2 Randomized trial design for hematuria evaluation comparing the standard approach and a marker-based approach. Int=intermediate. European Urology Oncology 2018 1, 223-230DOI: (10.1016/j.euo.2018.04.010) Copyright © 2018 European Association of Urology Terms and Conditions

Fig. 3 Randomized trial comparing surveillance with standard evaluation and standard evaluation with addition of a marker. European Urology Oncology 2018 1, 223-230DOI: (10.1016/j.euo.2018.04.010) Copyright © 2018 European Association of Urology Terms and Conditions